Adrenocortical carcinoma laboratory findings: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Adrenocortical carcinoma}} | {{Adrenocortical carcinoma}} | ||
{{CMG}} {{AE}} {{AAM}} | {{CMG}}; {{AE}} {{AAM}} {{MAD}} | ||
==Overview== | ==Overview== | ||
Some patients with adrenocortical carcinoma may have elevated concentration of serum [[cortisol]], [[aldosterone]], [[testosterone]] or [[estrogen]] and reduced concentration of plasma [[renin]] and [[potassium]]. | Some patients with adrenocortical carcinoma may have elevated concentration of serum [[cortisol]], [[aldosterone]], [[testosterone]] or [[estrogen]] and reduced concentration of plasma [[renin]] and [[potassium]]. | ||
Revision as of 16:24, 25 September 2017
|
Adrenocortical carcinoma Microchapters |
|
Differentiating Adrenocortical carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Study |
|
Adrenocortical carcinoma laboratory findings On the Web |
|
American Roentgen Ray Society Images of Adrenocortical carcinoma laboratory findings |
|
Risk calculators and risk factors for Adrenocortical carcinoma laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2] Mohammed Abdelwahed M.D[3]
Overview
Some patients with adrenocortical carcinoma may have elevated concentration of serum cortisol, aldosterone, testosterone or estrogen and reduced concentration of plasma renin and potassium.
Laboratory Findings
Laboratory findings that may associate adrenocortical carcinoma are:
| Hormonal disturbance | labs |
|---|---|
| Cortisol |
|
| Steroids[1] |
|
| Epinephrine[2] |
|
| Aldosterone[3] |
|
References
- ↑ Fassnacht M, Allolio B (2009). "Clinical management of adrenocortical carcinoma". Best Pract Res Clin Endocrinol Metab. 23 (2): 273–89. doi:10.1016/j.beem.2008.10.008. PMID 19500769.
- ↑ Song G, Joe BN, Yeh BM, Meng MV, Westphalen AC, Coakley FV (2011). "Risk of catecholamine crisis in patients undergoing resection of unsuspected pheochromocytoma". Int Braz J Urol. 37 (1): 35–40, discussion 40-1. PMID 21385478.
- ↑ Arlt W, Biehl M, Taylor AE, Hahner S, Libé R, Hughes BA; et al. (2011). "Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors". J Clin Endocrinol Metab. 96 (12): 3775–84. doi:10.1210/jc.2011-1565. PMC 3232629. PMID 21917861.